DelveInsight’s, “Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the Chronic Inflammatory Demyelinating Polyneuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Inflammatory Demyelinating Polyneuropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Inflammatory Demyelinating Polyneuropathy Research. Learn more about our innovative pipeline today! @ Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Outlook

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

• June 2024:- Immunovant Sciences GmbH– A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
• June 2024:- Janssen Research & Development LLC- Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
• DelveInsight’s Chronic Inflammatory Demyelinating Polyneuropathy pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Chronic Inflammatory Demyelinating Polyneuropathy treatment.
• The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies Inc., and others.
• Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies such as Riliprubart, Batoclimab 680 mg, SAR445088, Panzyga, Efgartigimod PH20 SC, Nipocalimab, IgPro10, Immunoadsorption, TAK-771, and others.

Stay informed about the cutting-edge advancements in Chronic Inflammatory Demyelinating Polyneuropathy Treatments. Download for updates and be a part of the revolution in inflammatory disease care @ Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials Assessment

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs Profile

• HYQVIA: Takeda

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It contains immunoglobulins collected from human plasma. The drug is infused under the skin into the fatty subcutaneous tissue. The hyaluronidase part of HYQVIA helps more of the Ig get absorbed into the body. The drug is approved for adults with primary immunodeficiency, and in adults, children and adolescents with PI and with secondary immunodeficiency. While it is in Phase III trial for CIDP.

• Rozanolixizumab: UCB S.A.

Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to the human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. The drug is under clinical development with the aim of improving the lives of people with pathogenic IgG-autoantibody-driven autoimmune diseases, including ITP, myasthenia gravis (MG), and CIDP, by driving the removal of pathogenic IgG autoantibodies.

• Temelimab: GeNeuro SA

Temelimab is a monoclonal antibody designed to neutralize a pathogenic viral envelope protein, encoded by a member of the Human Endogenous Retrovirus-W family, pHERV-W. This protein is thought to be a causal factor in several diseases, including multiple sclerosis, Type 1 diabetes and CIDP. It neutralizes the pHERV-W Env protein without targeting the patient’s immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease’s progress in all its forms. By neutralizing pHERV-W env, GNbAC1 could at the same time block these pathological inflammatory processes and restore remyelination in patients. The drug is currently in Phase I trial for the treatment of CIDP patients.

Learn more about Chronic Inflammatory Demyelinating Polyneuropathy Drugs opportunities in our groundbreaking Chronic Inflammatory Demyelinating Polyneuropathy Research and development projects @ Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Chronic Inflammatory Demyelinating Polyneuropathy Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Chronic Inflammatory Demyelinating Polyneuropathy Treatment by visiting our website. Stay informed about how we’re transforming the future of Neurology @ Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

• Coverage- Global
• Chronic Inflammatory Demyelinating Polyneuropathy Companies- Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies Inc., and others.
• Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 mg, SAR445088, Panzyga, Efgartigimod PH20 SC, Nipocalimab, IgPro10, Immunoadsorption, TAK-771, and others.
• Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Inflammatory Demyelinating Polyneuropathy Pipeline on our website @ Chronic Inflammatory Demyelinating Polyneuropathy Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Inflammatory Demyelinating Polyneuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Inflammatory Demyelinating Polyneuropathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. HYQVIA: Takeda
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Rozanolixizumab: UCB S.A.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Temelimab: GeNeuro SA
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
21. Chronic Inflammatory Demyelinating Polyneuropathy Key Products
22. Chronic Inflammatory Demyelinating Polyneuropathy- Unmet Needs
23. Chronic Inflammatory Demyelinating Polyneuropathy- Market Drivers and Barriers
24. Chronic Inflammatory Demyelinating Polyneuropathy- Future Perspectives and Conclusion
25. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Views
26. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/